CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
about
Modulation of CD6 function through interaction with Galectin-1 and -3T cell activation and differentiation is modulated by a CD6 domain 1 antibody ItolizumabJAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal DomainCD318 is a ligand for CD6.CD6 as a potential target for treating multiple sclerosisCD6 Receptor Regulates Intestinal Ischemia/Reperfusion-induced Injury by Modulating Natural IgM-producing B1a Cell Self-renewal.The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.Expression Profile of Three Splicing Factors in Pleural Cells Based on the Underlying Etiology and Its Clinical Values in Patients with Pleural Effusion.CD6 and Linker of Activated T Cells are Potential Interaction Partners for T Cell-Specific Adaptor Protein.Gene Expression Profiling in Behcet's Disease Indicates an Autoimmune Component in the Pathogenesis of the Disease and Opens New Avenues for Targeted Therapy.Human treg cells are characterized by low/negative CD6 expressionItolizumab (Alzumab), Mogamulizumab (Poteligeo), and Tositumomab (Bexxar)Small RNAs detected in exosomes derived from the MH7A synovial fibroblast cell line with TNF-α stimulation
P2860
Q24299519-FEAEDB20-CF8C-45F7-9331-7021BC780B66Q33865748-43488B92-4703-4A02-AC32-A07AF91BE33DQ35005863-D50C32EE-CDA3-4CE8-89D0-9E1BEEEF8629Q37334854-E73FABA7-0F5B-4E85-AEC6-7F40AC3516B0Q41476987-322D52DB-A0FC-4A0D-92CC-AAC5CC2EFFEFQ42177117-28EFE407-747C-4A2E-88AB-7C63E071216FQ48023143-B8E1C779-1D90-4FF6-B082-F87EFE518EACQ48265755-2F76E4B4-CF87-4F5E-9136-0698C706E729Q49390020-F3137F43-6065-4740-8D1F-55F895B8E1D3Q51298176-C359A840-466D-428F-9CE8-897591A75565Q55140887-8D1188A7-6B8D-41E2-AFAA-E360F05F872DQ56896657-A259E3B8-8A99-45CC-84B9-70134384EBE8Q58008014-471999C3-46E5-40CE-9C39-0A124D7E2AEAQ58791358-BD3DCF2D-C611-48D0-8923-6BA4F7CEDF18
P2860
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@ast
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@en
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@nl
type
label
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@ast
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@en
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@nl
prefLabel
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@ast
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@en
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
@nl
P2860
P1433
P1476
CD6 as a therapeutic target in autoimmune diseases: successes and challenges
@en
P2093
Alexandre M Carmo
Mafalda Pinto
P2860
P2888
P304
P356
10.1007/S40259-013-0027-4
P577
2013-06-01T00:00:00Z